Novel Agents in the Treatment of Lung Cancer
Fourth Cambridge Conference
September 2006
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
Thomas J. Lynch, Philip D. Bonomi, Charles Butts, Angela M. Davies, Jeffrey Engelman, Ramaswamy Govindan, Roy S. Herbst, John V. Heymach, Bruce E. Johnson, Renato G. Martins, Vincent A. Miller, Roman Perez-Soler, Gregory J. Riely, Alan B. Sandler, Lecia V. Sequist, Mark A. Socinski, Kwok-Kin Wong, and Carol S. Hart
Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
Roman Perez-Soler
HKI-272 in Non–Small Cell Lung Cancer
Kwok-Kin Wong
Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: The Current Status of Matuzumab and Panitumumab
Mark A. Socinski
Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
Daniel Morgensztern, Ramaswamy Govindan
Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine-Kinase Inhibitors
Philip Bonomi, Lela Buckingham, and John Coon
Bevacizumab in Non–Small Cell Lung Cancer
Alan Sandler
VEGF Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Emer O. Hanrahan, and John V. Heymach
VEGF Trap in Non–Small Cell Lung Cancer
Gregory J. Riely and Vincent A. Miller
Rationale for a Phase I Trial of Erlotinib and the mTOR inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Bruce E. Johnson, David Jackman, and Pasi A. Jänne
Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
Julie E. Bauman, Keith D. Eaton, and Renato G. Martins
The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Jeffrey A. Engelman
Enzastaurin, a Protein Kinase Cß–Selective Inhibitor, and its Potential Application as an Anticancer Agent in Lung Cancer
Roy S. Herbst, Yun Oh, Asavari Wagle, Michael Lahn
Incorporating Bortezomib into the Treatment of Lung Cancer
Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara
L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
Randeep Sangha and Charles Butts
